Filana Therapeutics Reports $90.9 Million Net Loss and Faces FDA Clinical Hold on Simufilam

Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) reported a significant decline in its financial performance for the fiscal year ending December 31, 2025, with a net loss of $90.9 million compared to a loss of $24.3 million in 2024. The company's accumulated deficit reached $496.1 million, reflecting ongoing challenges in its drug development efforts. Total operating expenses decreased to $95.4 million from $141.4 million in the previous year, primarily due to the discontinuation of its Alzheimer's disease program, which had previously incurred substantial costs. Research and development expenses fell by 62% to $26.6 million, while general and administrative expenses slightly decreased to $68.8 million.

In terms of strategic developments, Filana Therapeutics has shifted its focus to the development of simufilam, a drug candidate aimed at treating Tuberous Sclerosis Complex (TSC)-related epilepsy. The company entered into a License Agreement with Yale University in February 2025, granting it exclusive worldwide rights to certain intellectual property related to simufilam. This agreement includes milestone payments and royalties on net sales, which could impact future revenue streams if the drug is successfully commercialized. However, the company is currently facing a full clinical hold from the FDA on its planned clinical trials for simufilam, which has delayed its development timeline.

Operationally, Filana Therapeutics has reported a significant increase in accounts payable and accrued expenses, totaling $41.6 million as of December 31, 2025, compared to $7.7 million in the previous year. This increase is attributed to ongoing legal proceedings and settlements, including a $31.25 million settlement related to securities litigation. The company has also reduced its workforce by 33% in early 2025 to align its resources with its strategic goals following the discontinuation of its Alzheimer's program.

Looking ahead, Filana Therapeutics anticipates that its cash and cash equivalents of $95.5 million will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital to support its ongoing research and development activities, particularly in light of the clinical hold on simufilam. The future success of the company will depend on its ability to lift the clinical hold, secure regulatory approvals, and effectively commercialize its product candidates. The company remains committed to addressing the FDA's concerns and is working to provide the necessary information to resume its clinical trials.